504508337 08/17/2017

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4555042

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
ROBERTO TESTI	07/31/2017
OTTAVIANO INCANI	07/31/2017
ALESSANDRA RUFINI	07/31/2017
GABRIELLA DEMARTINO	07/31/2017

RECEIVING PARTY DATA

Name:	FRATAGENE THERAPEUTICS S.R.L.
Street Address:	VIALE DEI CAMPIONI 8
City:	ROMA
State/Country:	ITALY
Postal Code:	00144

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	14862072

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: jhuntley@kilpatricktownsend.com

Correspondent Name: KILPATRICK TOWNSEND & STOCKTON LLP

Address Line 1: 1420 5TH AVENUE

Address Line 2: SUITE 3700

Address Line 4: SEATTLE, WASHINGTON 98101

ATTORNEY DOCKET NUMBER:	097459-0957672
NAME OF SUBMITTER:	JORDAN HUNTLEY
SIGNATURE:	/Jordan Huntley/
DATE SIGNED:	08/17/2017

Total Attachments: 8

source=097459-000110US_X_Assignment#page1.tif source=097459-000110US_X_Assignment#page2.tif source=097459-000110US_X_Assignment#page3.tif

PATENT 504508337 REEL: 043321 FRAME: 0066

source=097459-000110US_X_Assignment#page4.tif
source=097459-000110US_X_Assignment#page5.tif
source=097459-000110US_X_Assignment#page6.tif
source=097459-000110US_X_Assignment#page7.tif
source=097459-000110US_X_Assignment#page8.tif

Attorney Docket No. 097459-000110US-0957672

ASSIGNMENT

(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility non-provisional patent application entitled

"COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA,"

filed with the U.S. Patent & Trademark Office on September 22, 2015

and assigned serial no. 14/862,072.

For one dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

- Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to Fratagene Therapeutics S.R.L., a company of the country of Italy having a principal place of business at Viale Dei Campioni 8, Roma, 00144 Italy ("Assignee"), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, and all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) the right to claim priority to the above-referenced patent application, and any and all applications referenced in subsection (b); and
 - (d) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and
 - (e) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including

provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.

- Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S.
 agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting
 from the intellectual property, patent application(s) and patents described in paragraph 1 of
 this Assignment.
- 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
- 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
- Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signature: Date: Date: Date: Date: Signature: Date: Da

69762717V.1

Gabriella DeMartino

ASSIGNMENT

(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility non-provisional patent application entitled

"COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA,"

filed with the U.S. Patent & Trademark Office on September 22, 2015

and assigned serial no. 14/862,072.

For one dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

- Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to Fratagene Therapeutics S.R.L., a company of the country of Italy having a principal place of business at Viale Dei Campioni 8, Roma, 00144 Italy ("Assignee"), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, and all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) the right to claim priority to the above-referenced patent application, and any and all applications referenced in subsection (b); and
 - (d) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and
 - (e) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including

provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.

- Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S.
 agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting
 from the intellectual property, patent application(s) and patents described in paragraph 1 of
 this Assignment.
- 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
- 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
- 5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

Signature:		Date:	·
٠	Roberto Testi		
Signature:	Offeriaceo becan'	Date:31.	.07. 2017
	Ottaviano Incani		
Signature:		Date:	
	Alessandra Rufini	·	
Signature:		Date:	
	Gabriella DeMartino		

69762717V.1

Attorney Docket No. 097459-000110US-0957672

ASSIGNMENT

(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility non-provisional patent application entitled

"COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA,"

filed with the U.S. Patent & Trademark Office on September 22, 2015

and assigned serial no. 14/862,072.

For one dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

- 1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to Fratagene Therapeutics S.R.L., a company of the country of Italy having a principal place of business at Viale Dei Campioni 8, Roma, 00144 Italy ("Assignee"), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, and all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) the right to claim priority to the above-referenced patent application, and any and all applications referenced in subsection (b); and
 - (d) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and
 - (e) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including

Signed on the dates indicated beside our signatures.

Gabriella DeMartino

provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.

- Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S.
 agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting
 from the intellectual property, patent application(s) and patents described in paragraph 1 of
 this Assignment.
- 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
- 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
- Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

69762717V.1

Attorney Docket No. 097459-000110US-0957672

ASSIGNMENT

(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility non-provisional patent application entitled

"COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA,"

filed with the U.S. Patent & Trademark Office on September 22, 2015

and assigned serial no. 14/862,072.

For one dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

- Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to Fratagene Therapeutics S.R.L., a company of the country of Italy having a principal place of business at Viale Dei Campioni 8, Roma, 00144 Italy ("Assignee"), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, and all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) the right to claim priority to the above-referenced patent application, and any and all applications referenced in subsection (b); and
 - (d) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and
 - (e) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including

provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.

- Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S.
 agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting
 from the intellectual property, patent application(s) and patents described in paragraph 1 of
 this Assignment.
- 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
- 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
- Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

Signature:		Date:	
	Roberto Testi	·	
Signature:		Date:	
	Ottaviano Incani	•	
Signature:		Date:	
	Alessandra Rufini		
Signature:	abollede lloch	Date:	31/07/2017
	Gabriella DeMartino		

69762717V.1

PATENT REEL: 043321 FRAME: 0075

RECORDED: 08/17/2017